0001461695-14-000003.txt : 20140423 0001461695-14-000003.hdr.sgml : 20140423 20140423111715 ACCESSION NUMBER: 0001461695-14-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140423 DATE AS OF CHANGE: 20140423 EFFECTIVENESS DATE: 20140423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nora Therapeutics, Inc. CENTRAL INDEX KEY: 0001461695 IRS NUMBER: 830509710 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-216080 FILM NUMBER: 14777985 BUSINESS ADDRESS: STREET 1: 530 LYTTON AVENUE, 2ND FLOOR CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 1-650-479-5331 MAIL ADDRESS: STREET 1: 530 LYTTON AVENUE, 2ND FLOOR CITY: PALO ALTO STATE: CA ZIP: 94301 D 1 primary_doc.xml X0707 D LIVE 0001461695 Nora Therapeutics, Inc. 530 LYTTON AVENUE, 2ND FLOOR PALO ALTO CA CALIFORNIA 94301 1-650-479-5331 DELAWARE None None Corporation true Jeffrey K. Tong c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Executive Officer Director Bryant E. Fong c/o Burrill Life Sciences Capital Fund One Embarcadero Center, Suite 2700 San Francisco CA CALIFORNIA 94111 Director David Schnell c/o Prospect Venture Partners III, LP 435 Tasso Street, Suite 200 Palo Alto CA CALIFORNIA 94301 Director Chen Yu c/o Vivo Ventures Fund VI, LP 575 High Street, Suite 201 Palo Alto CA CALIFORNIA 94301 Director Donald J. Hayden, Jr. c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Martin Vogelbaum c/o Rho Capital Partners 152 West 57th Street, 23rd Floor New York NY NEW YORK 10019 Director Dennis Fenton c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Biotechnology Decline to Disclose 06b false 2014-04-11 false true false 0 18000000 18000000 0 false 6 0 0 0 false Nora Therapeutics, Inc. /s/ Jeffrey K. Tong Jeffrey K. Tong President and CEO 2014-04-22